Last reviewed 2026-04-23 · How we verify

HCP1105

HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.

HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Metastatic castration-resistant prostate cancer (mCRPC).

At a glance

Mechanism of action

HCP1105 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide enhanced efficacy in androgen receptor-driven cancers.

Approved indications

• Castration-resistant prostate cancer (CRPC)
• Metastatic castration-resistant prostate cancer (mCRPC)

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Rash

Key clinical trials

• Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers (PHASE1)
• Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HCP1105 CI brief — competitive landscape report
• HCP1105 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI